Guideline for the treatment of patients with EPS In Alzheimer's disease.
Project/Area Number |
12670934
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Psychiatric science
|
Research Institution | Osaka University |
Principal Investigator |
IKEJIRI Yoshitaka Osaka University Graduate School of Medicine, Lecturer, 医学系研究科, 講師 (30294086)
|
Co-Investigator(Kenkyū-buntansha) |
NISHIKAWA Takashi Osaka University Graduate School of Medicine, Lecturer, 医学系研究科, 講師 (60273629)
TAKEDA Masatoshi Osaka University Graduate School of Medicine, Professor, 医学系研究科, 教授 (00179649)
中川 賀嗣 大阪大学, 医学系研究科, 助手 (40273718)
|
Project Period (FY) |
2000 – 2002
|
Project Status |
Completed (Fiscal Year 2002)
|
Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2002: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2001: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2000: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
Keywords | Alzheimer's disease / BPS (behavioral and psychological symptoms) / Acetylcholinesterase inhibitor / Serotonin-dopamine antagonist / Cognitive function / コリネステラーゼ阻害薬 / BPS(行動学的、精神学的症候) |
Research Abstract |
We examined effects of acetylcolinesterase inhibitor with and without serotonin-dipamine antagonist on BPS of Alzheimer's disease. Subjects were 39 patients with probable Alzheimer's disease who showed BPS and were with reliable caregivers. All they gave written informed consent. BPS included apathy, aberrant motor behavior, delusion, irritability, dysphoria, anxiety, disinhibition, and agitation. Acetylcholinesterase inhibitor with and without serotonin-dopamine antagonist were used for 11 and 28 patients of them, respectively. Aberrant motor behavior, delusion, irritability, and agitation were improved in the former group of patients, and apathy and dysphoria were improved in the latter group of patients. Results showed that acetylcholinesterase inhibitor improved apathy and dysphoria which were frequently associated with Alzheimer's disease, and that combined use of serotonin-dopamine antagonist were needed for treatment of aberrant motor behavior, delusion,irritability, and agitation.
|
Report
(4 results)
Research Products
(14 results)